2016 Fiscal Year Final Research Report
Inhibitory effects of combination therapy of denosumab, anti-RANKL antibody, and biological DMARD on bone and cartilage destruction in patients with rheumatoid arthritis
| Project/Area Number |
26462290
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KOJIMA Masayo 名古屋市立大学, 医学研究科, 准教授 (30326136)
|
|---|
| Research Collaborator |
YOSHIOKA Yutaka 半田市立半田病院, 整形外科
FUNAHASHI Koji 刈谷豊田総合病院, 整形外科
HIRABARA shinya 萩原整形外科リウマチクリニック
HIRANO Yuji 豊橋市民病院, リウマチ科, 部長
HAYASHI Masatoshi 長野赤十字病院, 整形外科
YABE Yuichiro JCHO東京新宿メディカルセンター, リウマチ科, 主任部長
OGUCHI Takeshi 安城更生病院, 整形外科
FUJIBAYASHI Takayoshi 愛知厚生連江南厚生病院, 整形外科リウマチ科, 部長
TAKAGI Hideki 名古屋セントラル病院, 整形外科
KANAYAMA Yasuhide 豊田厚生病院, 整形外科
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | rheumatoid arthritis / biologics / osteoporosis / denosumab |
|---|
| Outline of Final Research Achievements |
The purpose of this research project was to focus on the effect of antibody Denosumab on RANKL, which is particularly deeply related to bone resorption, and to elucidate the bone metabolism in rheumatoid arthritis (RA) and factors related to 1). The observation study of patients with Denosumab (TBCR-Bone), and 2). the specimen collection and analysis from RA surgical patients were encouraged. 1) About 76 registered RA patients were verified under real clinical practice up to 12 months, improved bone density, and suppression of bone metabolic markers were confirmed. The effects of disease activity were suggested. Ra-Bio, the steroid administration had no effect on Denosumab's effects. 2), bone cartilage collected during surgery from 25 patients, immunostaining and pathological evaluation of synovial membranes was performed.
|
| Free Research Field |
整形外科学
|
